LAG3 as a Cotherapy for Immune Checkpoints
Cotherapy with PD-1
Therapeutic antibodies targeting the immune checkpoint receptors PD-1 and CTLA4 substantially changed the prognosis for many cancer patients. When successful, these treatments extend lives. Still, cancer is relentless. Only a relatively small number of patients respond or have substantial remission when these treatments are used as monotherapies.
Much of the current research on immunomodulating r...
Citations
This page contains a list of scientific journal articles that have cited BPS products and services since 2013. We would like to congratulate all our loyal customers on their contributions to the scientific community. Our customers are truly amazing and dedicated scientists and this is evidenced by the outstanding research they are doing.
Search By Product Name or Catalog Number
Name
Title
10X HAT Assay Buffer (50095...
Methods For Drug Discovery
Immunotherapies based on targeting the PD-1:PD-L1 immune checkpoint pathway are having clinical impact and are giving new hope to cancer patients. However, positive response to treatment is not guaranteed and resistance remains a concern. Improving outcomes based on immunotherapy requires multiple approaches for manipulating the complexities of the immune system and tumor microenvironment. To meet these challenges, a series of r...
